Skip to main content

SurroMed and InterMune Start Biomarker Collaboration

NEW YORK, March 4 - SurroMed and InterMune are collaborating to discover new biomarkers, the companies said today.

 

SurroMed will analyze clinical samples provided by InterMune using its mass spectrometry-based technology.

 

InterMune hopes new biomarkers will help it better understand drug responses in ongoing clinical trials as well as find new drugs for pulmonary and hepatic disease.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.